Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

This exploratory open-label Phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA).

The trial was terminated in October 2022, citing a lack of participants, though possibly related to the acquisition of Eleusis by Beckley Psytech (funder of this trial).

Topic Pain Headache Disorders
Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Papers

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study
This open-label study (n=4) investigated the effects of low-dose oral psilocybin (5-10mg) with psychological support in patients with chronic short-lasting unilateral neuralgiform headache attacks (SUNHA). The study aimed to assess cognitive effects, safety, tolerability, and impact on headache severity and frequency, but was terminated early due to recruitment difficulties.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.